Takeda reports positive data from Phase IIb trial of ITP treatment

Takeda has unveiled positive results from its Phase IIb clinical trial of mezagitamab (TAK-079) for treating primary ITP.

The double-blind, randomised, placebo-controlled trial focused on assessing the safety, tolerability and efficacy of mezagitamab in people with this rare bleeding disorder.

In the trial, mezagitamab at doses of 100mg, 300mg and 600mg was assessed against placebo.